Literature DB >> 28277850

Diagnosis and management of catastrophic antiphospholipid syndrome.

Or Carmi1,2, Maya Berla1,2, Yehuda Shoenfeld2,3, Yair Levy1,2.   

Abstract

INTRODUCTION: Catastrophic antiphospholipid syndrome (CAPS) is a rare, life-threatening disease. In 1992, Asherson defined it as a widespread coagulopathy related to the antiphospholipid antibodies (aPL). CAPS requires rapid diagnosis and prompt initiation of treatment. Areas covered: This paper discusses all aspects of CAPS, including its pathophysiology, clinical manifestations, diagnostic approaches, differential diagnoses, management and treatment of relapsing CAPS, and its prognosis. To obtain the information used in this review, scientific databases were searched using the key words antiphospholipid antibodies, catastrophic antiphospholipid syndrome, hemolytic anemia, lupus anticoagulant, and thrombotic microangiopathic hemolytic anemia. Expert commentary: CAPS is a rare variant of the antiphospholipid syndrome (APS). It is characterized by thrombosis in multiple organs and a cytokine storm developing over a short period, with histopathologic evidence of multiple microthromboses, and laboratory confirmation of high aPL titers. This review discusses the diagnostic challenges and current approaches to the treatment of CAPS.

Entities:  

Keywords:  Antiphospholipid antibodies; catastrophic antiphospholipid syndrome; hemolytic anemia; lupus anticoagulant; thrombotic microangiopathic hemolytic anemia

Mesh:

Year:  2017        PMID: 28277850     DOI: 10.1080/17474086.2017.1300522

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  17 in total

1.  Characteristics and risk factors of an emergency department visit in patients with systemic lupus erythematosus.

Authors:  Yoshiki Nagai; Naoto Yokogawa; Kota Shimada; Shoji Sugii
Journal:  Rheumatol Int       Date:  2019-07-15       Impact factor: 2.631

2.  [Recurrent thrombocytopenia with hemolytic anemia in a boy aged 3 years].

Authors:  Min-Hui Zeng; Xiang-Ling He; Xin Tian; Yu-Hui Huang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2021-05

Review 3.  Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review).

Authors:  Eugenio Cavalli; Alessia Bramanti; Rosella Ciurleo; Andrey I Tchorbanov; Antonio Giordano; Paolo Fagone; Cristina Belizna; Placido Bramanti; Yehuda Shoenfeld; Ferdinando Nicoletti
Journal:  Int J Mol Med       Date:  2020-06-25       Impact factor: 4.101

4.  [Mechanisms and management of thrombosis and bleeding in antiphospholipid syndrome].

Authors:  Z Y Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-11-14

5.  SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?

Authors:  Marcella Prete; Elvira Favoino; Giacomo Catacchio; Vito Racanelli; Federico Perosa
Journal:  Autoimmun Rev       Date:  2020-05-01       Impact factor: 9.754

Review 6.  SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.

Authors:  Marcella Prete; Elvira Favoino; Giacomo Catacchio; Vito Racanelli; Federico Perosa
Journal:  Int J Mol Sci       Date:  2020-05-10       Impact factor: 5.923

Review 7.  Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?

Authors:  Ilaria Mormile; Francescopaolo Granata; Alessandra Punziano; Amato de Paulis; Francesca Wanda Rossi
Journal:  Biomedicines       Date:  2021-02-01

8.  Aspirin and heparin in the treatment of recurrent spontaneous abortion associated with antiphospholipid antibody syndrome: A systematic review and meta-analysis.

Authors:  Xiaomei Yu; Li He
Journal:  Exp Ther Med       Date:  2020-11-19       Impact factor: 2.447

Review 9.  COVID-19, Antiphospholipid Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association?

Authors:  Georges El Hasbani; Ali T Taher; Ali Jawad; Imad Uthman
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2020-12-03

10.  Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning.

Authors:  Yehuda Shoenfeld
Journal:  Autoimmun Rev       Date:  2020-04-05       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.